Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Centre of Emergency Medicine, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
Medicine (Baltimore). 2022 Jul 22;101(29):e29579. doi: 10.1097/MD.0000000000029579.
High-sensitivity troponin assay brought new challenges as we detect elevated concentration in many other diseases, and it became difficult to distinguish the real cause of this elevation. In this notion, diagnosis of acute coronary syndrome (ACS) remains a challenge in emergency department (ED). We aim to examine different approaches for rule-in and rule-out of ACS using risk scores, copeptin, and coronary computed tomography angiography (CCTA). A prospective observational study was designed to evaluate chest pain patients. Consecutive adult patients admitted to the ED with a chief complaint of chest pain due to any cause were included. All patients were followed-up for 6 months after discharge for major adverse cardiovascular events and readmissions. Admission data, ED processes, and diagnoses were analyzed. One hundred forty-six patients were included, average age was 63 ± 13.4 years, and 95 (65.1%) were male. Global Registry of Acute Coronary Events (GRACE) and History, ECG, Age, Risk factors, Troponin (HEART) scores showed good prognostic abilities, but HEART combination with copeptin improves diagnoses of myocardial infarction (area under the curve [AUC] 0.764 vs AUC 0.864 P = .0008). Patients with elevated copeptin were older, had higher risk scores, and were more likely to be admitted to hospital and diagnosed with ACS in ED. For copeptin, AUC was 0.715 (95% confidence interval 0.629-0.803), and for combination with troponin, AUC of 0.770 (0.703-0.855) did not improve rule-in of myocardial infarction. High-sensitivity troponin I assay alongside prior stroke, history of carotid stenosis, dyslipidemia, use of diuretics, and electrocardiogram changes (left bundle branch block or ST depression) are good predictors of myocardial infarction (χ² = 52.29, AUC = 0.875 [0.813-0.937], P < .001). The regression analysis showed that combination of copeptin and CCTA without significant stenosis can be used for ACS rule-out (χ² = 26.36, P < .001, AUC = 0.772 [0.681-0.863], negative predictive value of 96.25%). For rule-in of ACS, practitioner should consider not only scores for risk stratification but carefully analyze medical history and nonspecific electrocardiogram changes and even with normal troponin results, we strongly suggest thorough evaluation in chest pain unit. For rule-out of ACS combination of copeptin and CCTA holds great potential.
高敏肌钙蛋白检测带来了新的挑战,因为我们在许多其他疾病中也能检测到浓度升高,因此很难区分这种升高的真正原因。在这种情况下,急诊科(ED)对急性冠状动脉综合征(ACS)的诊断仍然具有挑战性。我们旨在使用风险评分、 copeptin 和冠状动脉计算机断层扫描血管造影(CCTA)来检查 ACS 的纳入和排除标准。设计了一项前瞻性观察研究来评估胸痛患者。连续纳入因任何原因导致胸痛为主诉而被收入 ED 的成年患者。所有患者在出院后 6 个月内进行主要不良心血管事件和再入院的随访。分析入院数据、ED 流程和诊断。共纳入 146 例患者,平均年龄 63±13.4 岁,95 例(65.1%)为男性。全球急性冠状动脉事件登记(GRACE)和病史、心电图、年龄、危险因素、肌钙蛋白(HEART)评分显示出良好的预后能力,但 HEART 联合 copeptin 可提高心肌梗死的诊断(曲线下面积[ AUC] 0.764 比 AUC 0.864,P=0.0008)。 copeptin 升高的患者年龄较大,风险评分较高,更有可能住院并在 ED 诊断为 ACS。对于 copeptin,AUC 为 0.715(95%置信区间 0.629-0.803),而与肌钙蛋白联合时,AUC 为 0.770(0.703-0.855),对心肌梗死的纳入没有改善作用。高敏肌钙蛋白 I 检测、既往卒中、颈动脉狭窄史、血脂异常、利尿剂使用和心电图改变(左束支传导阻滞或 ST 段压低)是心肌梗死的良好预测指标(χ²=52.29,AUC=0.875[0.813-0.937],P<.001)。回归分析表明, copeptin 联合无明显狭窄的 CCTA 可用于 ACS 的排除(χ²=26.36,P<.001,AUC=0.772[0.681-0.863],阴性预测值为 96.25%)。对于 ACS 的纳入,医生不仅应考虑风险分层评分,还应仔细分析病史和非特异性心电图改变,甚至在肌钙蛋白结果正常的情况下,我们强烈建议在胸痛单元进行全面评估。对于 ACS 的排除, copeptin 和 CCTA 的联合具有很大的潜力。